1. Home
  2. BNTX vs ILMN Comparison

BNTX vs ILMN Comparison

Compare BNTX & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BioNTech SE

BNTX

BioNTech SE

HOLD

Current Price

$95.46

Market Cap

24.8B

Sector

Health Care

ML Signal

HOLD

Logo Illumina Inc.

ILMN

Illumina Inc.

HOLD

Current Price

$135.59

Market Cap

18.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BNTX
ILMN
Founded
2008
1998
Country
Germany
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Medical Specialities
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
24.8B
18.9B
IPO Year
2019
2000

Fundamental Metrics

Financial Performance
Metric
BNTX
ILMN
Price
$95.46
$135.59
Analyst Decision
Buy
Hold
Analyst Count
11
16
Target Price
$137.40
$117.31
AVG Volume (30 Days)
1.6M
1.6M
Earning Date
11-03-2025
02-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
4.46
Revenue
$3,698,814,972.00
$4,288,000,000.00
Revenue This Year
$2.03
N/A
Revenue Next Year
N/A
$2.24
P/E Ratio
N/A
$30.34
Revenue Growth
3.70
N/A
52 Week Low
$81.20
$68.70
52 Week High
$129.27
$153.06

Technical Indicators

Market Signals
Indicator
BNTX
ILMN
Relative Strength Index (RSI) 45.60 62.29
Support Level $91.32 $129.29
Resistance Level $93.76 $138.80
Average True Range (ATR) 2.09 3.96
MACD 0.18 -0.36
Stochastic Oscillator 46.39 71.84

Price Performance

Historical Comparison
BNTX
ILMN

About BNTX BioNTech SE

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.

About ILMN Illumina Inc.

Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.

Share on Social Networks: